A Phase II Clinical Trial in Newly Diagnosed Glioblastoma Patients Treated with WP1066 and Radiation
新诊断的胶质母细胞瘤患者接受 WP1066 和放射治疗的 II 期临床试验
基本信息
- 批准号:10658700
- 负责人:
- 金额:$ 60.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-05 至 2028-04-30
- 项目状态:未结题
- 来源:
- 关键词:Animal ModelAnimalsAntigen PresentationAntigen-Presenting CellsAntitumor ResponseBlood - brain barrier anatomyBrainBrain NeoplasmsBrain Stem GliomaCD11c AntigensCD3 AntigensCell physiologyCellsCellular immunotherapyChildhoodClinicalClinical TrialsCombined Modality TherapyDendritic CellsDendritic cell activationDependenceDoseDrug KineticsEducationEffectivenessExcisionFlow CytometryGlioblastomaGliomagenesisGoalsHeterogeneityHigh Pressure Liquid ChromatographyHumanImmuneImmune responseImmune systemImmunocompromised HostImmunohistochemistryImmunologicsImmunosuppressionImmunotherapyInfiltrationInflammatory ResponseLesionMGMT geneMagnetic Resonance ImagingMalignant NeoplasmsMapsMemoryMetastatic malignant neoplasm to brainMicrogliaModelingMusMyeloid CellsNatural ImmunityNewly DiagnosedOperative Surgical ProceduresOutcomePathway interactionsPatientsPharmaceutical PreparationsPhase I Clinical TrialsPhase II Clinical TrialsPhenotypePopulationProgression-Free SurvivalsRadiationRadiation therapyRecurrenceResearchSignal InductionStat3 proteinT cell infiltrationT-Cell ActivationT-LymphocyteTestingTextureTissuesUniversitiesValidationadaptive immunitycancer cellcohortfirst-in-humanimmune activationimmune clearanceimmunogenicityimprovednano-stringneuro-oncologypharmacodynamic biomarkerpharmacologicphase 3 studyphase I trialphase II trialpre-clinicalpreclinical studyradiological imagingresponsesmall molecule inhibitorstandard of caretumortumor microenvironmenttumor-immune system interactions
项目摘要
SUMMARY
The brain tumor microenvironment (TME) is dominated by myeloid cell infiltrates which are mostly brain resident
microglia and infiltrating glioblastoma-associated myeloid cells (GAMs). Despite this fact, most clinical trials for
glioblastoma have been directed to T cell-based immunotherapies, which have failed to impact outcome for most
patients. Targeting glioblastoma based on re-education of GAMS to enable immunological clearance is the goal
of this clinical trial. The signal transducer and activator of transcription 3 (STAT3) is a negative regulator of both
innate and adaptive immunity and this pathway is markedly up regulated in the TME. We have previously
developed and tested, in the context of Phase I clinical trials, a first-in-man blood-brain-barrier penetrant small
molecule inhibitor of STAT3, designated WP1066. The Phase I trial results have shown that WP1066 is well
tolerated and is inhibiting the STAT3 target in immune cells. As a monotherapy, WP1066 treatment has
demonstrated the ability to stimulate robust anti-tumor response in multiple preclinical studies that is further
enhanced with radiation therapy, which is standard of care for newly diagnosed glioblastoma and is known to
increase tumor immunogenicity. Unbiased nanostring analysis of treated tumors revealed that activation of
antigen presentation in the TME with the combination treatment. For the research proposed here we want to
extend our preclinical findings to newly diagnosed glioblastoma patients. In this clinical trial, we will test the
hypothesis that the administration of WP1066 with radiation will induce T cell-dendritic cell cluster interactions in
the glioblastoma microenvironment, and this induction, in turn, will increase progression free survival (PFS) for
glioblastoma patients. In specific Aim 1, we conduct a Phase II trial with an expansion cohort for the combination
of WP1066 and radiation in newly diagnosed MGMT unmethylated glioblastoma patients. In cohort 1, newly
diagnosed MGMT unmethylated, IDH1 wild-type glioblastoma patients will be treated with 8 mg/kg of WP1066
while undergoing standard-of-care radiation therapy at a daily dose of 2 Gy. PFS will be used to ascertain if there
is indication of treatment benefit. In cohort 2, patients for whom gross total resection was not achieved will be
treated with the combination of radiation and WP1066 with the intent of obtaining treated tumor, if a surgically
amenable lesion is present. Such tissue would allow for analysis of TME immune activation and cluster
interactions, drug concentrations and target engagement in Aim 2. Aim 2 will also use longitudinal textural MRI
analysis to correlate inflammatory responses in the TME by using our STAT3-specific multiplex immune
fluorescent panel and complementary ex vivo flow cytometry and nanostring profiling. STAT3 target inhibition,
including within specific immune cell populations, will be ascertained through use of the multiplex panel, which
will also inform regarding the induction of cluster interactions in the tumor. HPLC quantification of WP1066
concentrations in both enhancing and non-enhancing tumor will be used to determine drug pharmacokinetics. In
Aim 3, we will clarify which human GAMs in the TME trigger T cell activation, and if such activation is altered by
STAT3 inhibition.
总结
脑肿瘤微环境(TME)主要由髓样细胞浸润所支配,其中大多数是脑驻留细胞
小胶质细胞和浸润性胶质母细胞瘤相关髓样细胞(GAM)。尽管如此,大多数临床试验
胶质母细胞瘤已被导向基于T细胞的免疫疗法,这未能影响大多数人的结果。
患者目标是基于GAMS的再教育来靶向胶质母细胞瘤,以实现免疫清除
这个临床试验。信号转导子和转录激活子3(STAT3)是这两个信号转导子和转录激活子的负调节子。
先天性和适应性免疫,并且该途径在TME中显著上调。我们先前已经
在I期临床试验的背景下,开发并测试了第一种人体血脑屏障渗透剂,
STAT3分子抑制剂,命名为WP 1066。第一阶段试验结果表明,WP 1066是良好的
耐受,并抑制免疫细胞中的STAT3靶点。作为单一疗法,WP 1066治疗具有
在多项临床前研究中证明了刺激强大的抗肿瘤反应的能力,
放射治疗是新诊断的胶质母细胞瘤的标准治疗,
增加肿瘤免疫原性。治疗肿瘤的无偏纳米线分析显示,
在TME中的抗原呈递。对于这里提出的研究,我们希望
将我们的临床前发现扩展到新诊断的胶质母细胞瘤患者。在这项临床试验中,我们将测试
假设WP1066与辐射一起施用将诱导T细胞-树突状细胞簇相互作用,
胶质母细胞瘤微环境,这种诱导,反过来,将增加无进展生存期(PFS),
胶质母细胞瘤患者。在具体的目标1中,我们进行了一项II期试验,其中有一个扩展队列用于联合治疗。
WP1066和放射治疗在新诊断的MGMT未甲基化胶质母细胞瘤患者中的作用。在队列1中,
诊断为MGMT未甲基化的IDH1野生型胶质母细胞瘤患者将用8mg/kg的WP 1066治疗
同时接受每日剂量为2戈伊的标准护理放射治疗。PFS将用于确定是否有
是治疗获益的指标。在队列2中,将对未实现大体全切除的患者进行
用放射和WP 1066的组合治疗,目的是获得治疗的肿瘤,如果手术治疗,
存在易受损伤的病变。这样的组织将允许分析TME免疫活化和簇集。
目标2中的相互作用、药物浓度和靶点参与。Aim 2还将使用纵向纹理MRI
通过使用我们的STAT3特异性多重免疫分析TME中的相关炎症反应
荧光板和互补的离体流式细胞术和纳米线分析。STAT3靶点抑制,
包括特异性免疫细胞群内的免疫细胞的免疫学特性将通过使用多重组来确定,
还将告知关于肿瘤中簇相互作用的诱导。WP 1066的HPLC定量
在增强和非增强肿瘤中的浓度将用于确定药物药代动力学。在
目的3,我们将阐明TME中哪些人GAM触发T细胞活化,以及这种活化是否被TME改变。
STAT3抑制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Amy Beth Heimberger其他文献
Amy Beth Heimberger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Amy Beth Heimberger', 18)}}的其他基金
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse
Fgl2中和疗法诱导肿瘤特异性脑常驻免疫记忆对抗中枢神经系统肿瘤复发
- 批准号:
10655501 - 财政年份:2021
- 资助金额:
$ 60.18万 - 项目类别:
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse
Fgl2中和疗法诱导肿瘤特异性脑常驻免疫记忆对抗中枢神经系统肿瘤复发
- 批准号:
10275974 - 财政年份:2021
- 资助金额:
$ 60.18万 - 项目类别:
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse
Fgl2中和疗法诱导肿瘤特异性脑常驻免疫记忆对抗中枢神经系统肿瘤复发
- 批准号:
10454240 - 财政年份:2021
- 资助金额:
$ 60.18万 - 项目类别:
STINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBM
刺痛 GBM:可手术切除复发性 GBM 的首次人体临床试验
- 批准号:
10626394 - 财政年份:2018
- 资助金额:
$ 60.18万 - 项目类别:
Fgl-2 targeted therapy for reversing multi-modality immune suppression
Fgl-2靶向治疗逆转多模式免疫抑制
- 批准号:
9152967 - 财政年份:2016
- 资助金额:
$ 60.18万 - 项目类别:
Targeting Malignant Gliomas with a Novel Inhibitor of the STAT3 Pathway
用 STAT3 通路的新型抑制剂靶向恶性胶质瘤
- 批准号:
8588570 - 财政年份:2008
- 资助金额:
$ 60.18万 - 项目类别:
Targeting Malignant Gliomas with a Novel Inhibitor of the STAT3 Pathway
用 STAT3 通路的新型抑制剂靶向恶性胶质瘤
- 批准号:
8753979 - 财政年份:2008
- 资助金额:
$ 60.18万 - 项目类别:
Targeting Malignant Gliomas with a Novel Inhibitor of the STAT3 Pathway
用 STAT3 通路的新型抑制剂靶向恶性胶质瘤
- 批准号:
9339983 - 财政年份:2008
- 资助金额:
$ 60.18万 - 项目类别:
相似海外基金
The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
- 批准号:
EP/Z000920/1 - 财政年份:2025
- 资助金额:
$ 60.18万 - 项目类别:
Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
- 批准号:
FT230100276 - 财政年份:2024
- 资助金额:
$ 60.18万 - 项目类别:
ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
- 批准号:
MR/X024261/1 - 财政年份:2024
- 资助金额:
$ 60.18万 - 项目类别:
Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
- 批准号:
DE240100388 - 财政年份:2024
- 资助金额:
$ 60.18万 - 项目类别:
Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
- 批准号:
2889694 - 财政年份:2023
- 资助金额:
$ 60.18万 - 项目类别:
Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
- 批准号:
2842926 - 财政年份:2023
- 资助金额:
$ 60.18万 - 项目类别:
Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
- 批准号:
NC/X001644/1 - 财政年份:2023
- 资助金额:
$ 60.18万 - 项目类别:
Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
- 批准号:
2337595 - 财政年份:2023
- 资助金额:
$ 60.18万 - 项目类别:
Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
- 批准号:
2232190 - 财政年份:2023
- 资助金额:
$ 60.18万 - 项目类别:
Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
- 批准号:
23K17514 - 财政年份:2023
- 资助金额:
$ 60.18万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)